EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Saliva and Saliva Extracellular Vesicles for Biomarker Candidate Identification—Assay Development and Pilot Study in Amyotrophic Lateral Sclerosis

Sebastian Sjoqvist, Kentaro Otake

International Journal of Molecular Sciences · 09.03.2023 · 24 (6) · 5237

DOI: 10.3390/ijms24065237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.03.2023. Verfasst von Sebastian Sjoqvist und 1 weiteren Autor:innen. Beteiligte Einrichtung: Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa 251-8555, Japan. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Extracellular Vesicles. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Saliva is gaining increasing attention as a source of biomarkers due to non-invasive and undemanding collection access. Extracellular vesicles (EVs) are nano-sized, cell-released particles that contain molecular information about their parent cells. In this study, we developed methods for saliva biomarker candidate identification using EV-isolation and proteomic evaluation. We used pooled saliva samples for assay development. EVs were isolated using membrane affinity-based methods followed by their characterization using nanoparticle tracking analysis and transmission electron microscopy. Subsequently, both saliva and saliva-EVs were successfully analyzed using proximity extension assay and label-free quantitative proteomics. Saliva-EVs had a higher purity than plasma-EVs, based on the expression of EV-proteins and albumin. The developed methods could be used for the analysis of individual saliva samples from amyotrophic lateral sclerosis (ALS) patients and controls (n = 10 each). The starting volume ranged from 2.1 to 4.9 mL and the amount of total isolated EV-proteins ranged from 5.1 to 42.6 µg. Although no proteins were significantly differentially expressed between the two groups, there was a trend for a downregulation of ZNF428 in ALS-saliva-EVs and an upregulation of IGLL1 in ALS saliva. In conclusion, we have developed a robust workflow for saliva and saliva-EV analysis and demonstrated its technical feasibility for biomarker discovery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisExtracellular VesiclesHumansPilot ProjectsProteomicsSalivaBiomarkers

Stichwörter der Autor:innen

amyotrophic lateral sclerosisbiomarkersextracellular vesiclessaliva

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Neuroscience Drug Discovery Unit, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa 251-8555, Japan.

Zitieren

APA

Sjoqvist, S., & Otake, K. (2023). Saliva and Saliva Extracellular Vesicles for Biomarker Candidate Identification—Assay Development and Pilot Study in Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences, 24(6), 5237. https://doi.org/10.3390/ijms24065237

Vancouver

Sjoqvist S, Otake K. Saliva and Saliva Extracellular Vesicles for Biomarker Candidate Identification—Assay Development and Pilot Study in Amyotrophic Lateral Sclerosis. International Journal of Molecular Sciences. 2023;24(6):5237. doi:10.3390/ijms24065237

BibTeX
@article{Sjoqvist2023,
  author = {Sjoqvist, Sebastian and Otake, Kentaro},
  title = {Saliva and Saliva Extracellular Vesicles for Biomarker Candidate Identification—Assay Development and Pilot Study in Amyotrophic Lateral Sclerosis},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {6},
  pages = {5237},
  doi = {10.3390/ijms24065237}
}
Kostenlos starten →